Profusa Adds a Leading French Critical Limb Ischemia Surgeon to Customer Base

Core Insights - Profusa, Inc. has expanded its customer base in Europe through a collaboration with Prof. Yann Gouëffic, who treats approximately 8% of all critical limb threatening ischemia (CLTI) cases in France [1][2][3] - The partnership will involve the adoption of Profusa's Lumee™ oxygen monitoring technology in clinical practices and studies, aimed at improving patient outcomes during recovery at home [2][3] - Prof. Gouëffic has over 20 years of experience in vascular surgery and has been a principal investigator in numerous clinical trials related to lower limb peripheral artery disease [2] Company Overview - Profusa is a commercial stage digital health company based in Berkeley, California, focused on developing tissue-integrated sensors for continuous monitoring of biochemistry [4] - The company aims to provide affordable, long-lasting biosensors and an intelligent data platform to deliver personalized biochemical data for medical use [4] Market Potential - The endovascular market in Europe is significant, with an estimated 300,000 procedures conducted annually, indicating a large clinical need for real-time biochemistry monitoring solutions [3]